v3.25.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Net Product Sales, Cost of Product Sales and Gross Profit for Each Commercial Products
Total revenues, cost of sales, and gross profit (loss) for each of our commercial products and other were as follows (in millions):
Three Months Ended March 31,
2025
Tyvaso DPI(1)
Nebulized Tyvaso(1)
Remodulin(2)
OrenitramUnituxinAdcircaOtherTotal
Total revenues$302.5 $163.8 $138.2 $120.7 $58.2 $6.0 $5.0 $794.4 
Cost of sales48.1 8.5 13.8 8.3 5.2 2.6 6.0 92.5 
Gross profit (loss)$254.4 $155.3 $124.4 $112.4 $53.0 $3.4 $(1.0)$701.9 
2024
Total revenues$227.5 $145.0 $128.0 $106.2 $58.4 $6.4 $6.2 $677.7 
Cost of sales33.3 8.9 7.9 9.2 3.6 2.6 7.4 72.9 
Gross profit (loss)
$194.2 $136.1 $120.1 $97.0 $54.8 $3.8 $(1.2)$604.8 
(1) Total revenues and cost of sales include both the drug product and the respective inhalation device.
(2) Total revenues and cost of sales include sales of infusion devices, including the Remunity Pump.
Schedule of Net Revenues from External Customers by Geographic Area
Geographic revenues are determined based on the country in which our customers (distributors) are located. Total revenues from external customers in the United States and rest-of-world (ROW) for each of our commercial products were as follows (in millions):
Three Months Ended March 31,
20252024
U.S.ROWTotalU.S.ROWTotal
Net product sales:
Tyvaso DPI(1)
$302.5 $— $302.5 $227.5 $— $227.5 
Nebulized Tyvaso(1)
138.6 25.2 163.8 133.7 11.3 145.0 
Total Tyvaso
441.1 25.2 466.3 361.2 11.3 372.5 
Remodulin(2)
120.2 18.0 138.2 108.3 19.7 128.0 
Orenitram
120.7 — 120.7 106.2 — 106.2 
Unituxin
56.9 1.3 58.2 53.4 5.0 58.4 
Adcirca
6.0 — 6.0 6.4 — 6.4 
Other4.7 0.3 5.0 6.0 0.2 6.2 
Total revenues
$749.6 $44.8 $794.4 $641.5 $36.2 $677.7 
(1) Net product sales include both the drug product and the respective inhalation device.
(2) Net product sales include sales of infusion devices, including the Remunity Pump.
Schedule of Revenue from Two Specialty Pharmaceutical Distributors in the United States as a Percentage of Total Revenue
We recorded revenue from two distributors in the United States that exceeded ten percent of total revenues. Revenue from these two distributors as a percentage of total revenues is as follows:
Three Months Ended March 31,
20252024
Distributor 152 %51 %
Distributor 234 %34 %